SOPHIA ANTIPOLIS, France – November 21, 2025 │ October 21, 2025 – Takeda has entered into a license and collaboration agreement with Innovent Biologics for the development, manufacturing and commercialization of two late-stage oncology medicines, worldwide outside of Greater China. First, there is IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein, evaluated in non-small cell lung[…]
SOPHIA ANTIPOLIS, France – October 24, 2025 │ Hansoh Pharmaceutical has signed a license agreement with Roche to develop HS-20110, a CDH17-targeting antibody-drug conjugate (ADC) utilizing a clinically validated topoisomerase inhibitor payload. Hansoh Pharma gives Roche an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to advance the clinical development and[…]
SOPHIA ANTIPOLIS, France – October 17, 2025 │ This quarter, KnowMade’s Therapeutic mRNA patent monitoring service reveals two emerging players shaping the next wave of RNA innovation: Parcel Bio, pioneering nanoparticle-free delivery, and ArkeaBio, developing mRNA vaccines for methane mitigation. Two Emerging Players Expand the Frontiers of Therapeutic mRNA Innovation Two new entrants have emerged[…]
SOPHIA ANTIPOLIS, France – July 16, 2025 │ KnowMade actively tracks therapeutic mRNA innovations as part of its Therapeutic mRNA patent monitoring service. What’s new today? Spotlight on Emerging Innovators: The Strategic Value of Patent Monitoring The first half of 2025 confirms the ongoing momentum in therapeutic mRNA innovation, as highlighted in KnowMade’s press release[…]